SCOPE 2026

R&D

SCOPE 2026 was dominated by one big topic: AI. You couldn’t walk five steps without hearing about something that AI was going to fix.

News

Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.